HOME >> BIOLOGY >> NEWS
Antegren (natalizumab) clinical study results published in New England Journal of Medicine

Dublin, Ireland and Cambridge, MA, January 2, 2003 Elan Corporation, plc (NYSE: ELN) ("Elan") and Biogen, Inc. (NASDAQ: BGEN) ("Biogen") announce the publication of two clinical study reports on ANTEGREN (natalizumab) in today's issue of the New England Journal of Medicine. Natalizumab, a humanized monoclonal antibody, showed promising results on disease remission and improved quality of life for patients with Crohn's disease in an investigational study, according to results published today. Crohn's disease, a chronic, progressive and immune-related inflammatory disease of the gastrointestinal tract, can cause a range of debilitating symptoms such as severe diarrhea, crampy abdominal pain and malnutrition. Current treatment options for the disease are limited.

Crohn's Disease Study Design and Results
The randomized, double-blind, placebo-controlled, parallel group, Phase II study of 248 patients with Crohn's disease presented in the New England Journal of Medicine was conducted in eight countries at 35 clinical trial sites. Patients were randomized to one of four treatment groups: single 3 mg/kg natalizumab infusion followed by placebo (n=68); two 3 mg/kg natalizumab infusions at four-week intervals (n=66); two 6 mg/kg natalizumab infusions at four-week intervals (n=51), or placebo (n=63) and all groups were observed for at least 12 weeks following the first infusion. Patients with moderate- to-severe active Crohn's disease (Crohn's Disease Activity Index ("CDAI") scores of 220 to 450) were included in the study. The primary measure of effectiveness was clinical remission: a score of less than 150 on the CDAI. Clinical response was defined as a decrease of at least 70 points in the CDAI from baseline. Additional efficacy measures included quality of life assessments, as determined by the Inflammatory Bowel Disease Questionnaire ("IBDQ").

Although the primary endpoint of remission at 6 weeks in the 6 mg/kg dose group compared to plac
'"/>

Contact: Amy Losak
amy.losak@ketchum.com
646-935-3917
Ketchum
1-Jan-2003


Page: 1 2 3 4

Related biology news :

1. Clinical study results published in NEJM show promising data on Antegren (natalizumab)
2. Preclinical safety study shows adipose-derived stem cells improve heart function after heart attack
3. First clinical study of new pediatric croup vaccine shows safety, tolerability in adults
4. Innovative ceramic-on-metal hip replacements to undergo clinical trials
5. Early clinical treatment can halt progression of Alzheimers disease, UCI researchers find
6. Warren Pharmaceuticals publishes results of preclinical evaluation
7. Creation of the UK Clinical Research Collaboration will boost clinical trials in UK
8. Scientists characterize new breast tumor subtypes with poor clinical outcomes
9. Uncertainty in clinical tests raises health care costs
10. Vanderbilts John Oates wins clinical research award
11. Germany starts clinical development of a new tuberculosis vaccine

Post Your Comments:
(Date:6/18/2013)... Kingdom, the Energy Department,s National Renewable Energy Laboratory ... published a paper describing a novel cellulose-degrading enzyme ... , commonly known as the gribble. , ... relatively unique ability to produce their own enzymes ... the biomass they eat. New biomass-degrading enzymes from ...
(Date:6/18/2013)... Scientists are expecting a very large "dead zone" in ... hypoxic level in the Chesapeake Bay this year, based ... the University of Michigan, Louisiana State University, and the ... year,s Gulf of Mexico hypoxic "dead" zone will be ... it among the ten largest recorded. That would range ...
(Date:6/18/2013)... June 18, 2013 Joshua Obar, Ph.D., Department of ... honored with a 2013 ICAAC Young Investigator Award for ... immunological memory responses to infection. , Obar earned ... 2001 and went on to complete his Ph.D. in ... He performed his Ph.D. thesis research in Edward Usherwood,s ...
Breaking Biology News(10 mins):Novel enzyme from tiny gribble could prove a boon for biofuels research 2NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 2NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 3NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 4The American Society for Microbiology honors Joshua Obar 2
(Date:6/18/2013)... Israel , June 18, 2013 ... Pharmaceutical Ingredients (APIs), generic and innovative intermediates, and finished dosage ... the company has been granted a United States ... US and Europe for the oral ... 8,410,176 B2 is titled Intermediate Compounds and Processes for ...
(Date:6/18/2013)... June 18, 2013 ... announced the addition of the "Injectable ... & Nanoparticles], Devices [Disposables & Reusable, Fillable ... Injectors] & Therapeutics [Diabetes & Oncology] - ... their offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ...
(Date:6/18/2013)... Though health care jobs continued to ... Bureau of Labor Statistics -- the increase was far below ... new health care jobs were added in home health care ... of 6,000 jobs. Overall, the U.S. unemployment rate stayed flat ... Christmas reported that a total of just over 36,000 job ...
(Date:6/18/2013)... Earlier this year, Google announced the new ‘enhanced campaign’ ... impacts the core component of the product, the campaign, many ... updates since its inception in October of 2000. The ... very informative article on the subject.. , Google ... enhanced campaigns . Only recently, a date of July ...
Breaking Biology Technology:Mapi Pharma Granted United States Patent for Pain Relief Medication "Tapentadol" 2Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 2Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 3MedZilla Employment Report for June 2013 -- Jobs in Health Care Grow, But at Slower Pace 2MedZilla Employment Report for June 2013 -- Jobs in Health Care Grow, But at Slower Pace 3Core and More Technologies Helps Organizations Migrate to Google’s Enhanced Campaign Structure 2Core and More Technologies Helps Organizations Migrate to Google’s Enhanced Campaign Structure 3
Cached News: